Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetyllevocarnitine Hydrochloride in DPN Paresthesia
NCT05319275Phase 3Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jul 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic peripheral neuropathy (DPN) comparing Acetyllevocarnitine Hydrochloride with Placebo (2 arms). Primary endpoint: modified Toronto Clinical Neuropathy Score total score change from baseline at 24 weeks. Started Jul 2020; status: completed.
02
Drugs
acetyl-l-carnitine
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT05319275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05319275.